Domperidone is a dopamine antagonist used to treat upper GI motility disorders associated with chronic gastritis and diabetic gastroparesis. It works by blocking peripheral dopamine receptors in the GI tract, increasing esophageal peristalsis and gastric emptying. Common adverse reactions include headache, dry mouth, and cardiac issues like QT prolongation. It should not be used in patients with hypersensitivity, GI bleeding, or long QT syndrome. Care should be taken if using other QT prolonging drugs or ketoconazole due to drug interaction risks.
Domperidone is a dopamine antagonist used to treat upper GI motility disorders associated with chronic gastritis and diabetic gastroparesis. It works by blocking peripheral dopamine receptors in the GI tract, increasing esophageal peristalsis and gastric emptying. Common adverse reactions include headache, dry mouth, and cardiac issues like QT prolongation. It should not be used in patients with hypersensitivity, GI bleeding, or long QT syndrome. Care should be taken if using other QT prolonging drugs or ketoconazole due to drug interaction risks.
Domperidone is a dopamine antagonist used to treat upper GI motility disorders associated with chronic gastritis and diabetic gastroparesis. It works by blocking peripheral dopamine receptors in the GI tract, increasing esophageal peristalsis and gastric emptying. Common adverse reactions include headache, dry mouth, and cardiac issues like QT prolongation. It should not be used in patients with hypersensitivity, GI bleeding, or long QT syndrome. Care should be taken if using other QT prolonging drugs or ketoconazole due to drug interaction risks.
Domperidone is a dopamine antagonist used to treat upper GI motility disorders associated with chronic gastritis and diabetic gastroparesis. It works by blocking peripheral dopamine receptors in the GI tract, increasing esophageal peristalsis and gastric emptying. Common adverse reactions include headache, dry mouth, and cardiac issues like QT prolongation. It should not be used in patients with hypersensitivity, GI bleeding, or long QT syndrome. Care should be taken if using other QT prolonging drugs or ketoconazole due to drug interaction risks.
Dopamine o Symptomatic o Headache/migraine 1 Hypersensitivity to Avoid use in
Generic Antagonist management of upper Chemical Effect: o Xerostomia (Dry mouth). domperidone or any patients with Name: Domperidone GI motility disorders component of the diagnosed or Altered cardiac conduction: suspected associated with QT c prolongation, life- formulation. congenital long chronic and subacute threatening tachyarrhythmias 2 patients with GI QT syndrome. Brand Name: Dompy, gastritis and diabetic (eg, torsade de pointes), and hemorrhage, Motilium cardiac arrest have been mechanical gastroparesis. Domperidone reported after use; these adverse o prevention of GI obstruction, or may enhance the effects may be precipitated in symptoms associated hypokalemic patients or in perforation. QTc-prolonging Doase, Route & 3 concomitant use with use of Therapeutic Effect: patients receiving other QT c - effect of Frequency : prolonging agents with ketoconazole. dopamine-agonist o Domperidone Ketoconazole Available as Tablets & o anti-Parkinson has peripheral (Systemic). Syrup agents. dopamine (D2) Ketoconazole o Usual dose : receptor (Systemic) may ORALLY (P.O) 10 mg 3-4 blocking increase the times/day, 15- properties and serum 30 minutes does not readily concentration of before meals cross the blood- Domperidone. and at bedtime brain barrier so , Risk X: Avoid if needed. less likely to combination o 20 mg 3-4 cause times/day extrapyramidal Monitor patient (higher doses side effects. It may be increases necessary esophageal during titration peristalsis and of anti- increases lower Parkinson esophageal therapy). sphincter pressure, increases gastric motility and peristalsis, and enhances gastroduodenal coordination, therefore, facilitating gastric emptying and decreasing small bowel transit time. o The antiemetic properties of dopamine are related to its dopamine receptor blocking activity at both the chemoreceptor trigger zone and at the gastric level.